Graphic: corner
spacer
Graphic: corner
spacer spacer
nav left edge
nav right edge
spacer

Acral Mutilation Syndrome         AMS Test         Code 250

Test Pricing

For breeds: English Cocker Spaniel, English Pointer, English Springer Spaniel, French Spaniel, German Shorthaired Pointer

Clinical signs/Disease description:

The term acral refers to peripheral parts of body, such as limbs, fingers, or toes. Acral Mutilation Syndrome (AMS) in dogs is a rare inherited sensory neuropathy that results in insensitivity to pain and progressive mutilation of the distal extremities. Affected dogs lick, bite and severely self-mutilate their distal extremities. Auto-amputation of claws, digits and footpads occurs in severe cases.

Affected dogs may be identified soon after birth by their lack of response to acral pinprick or compression. However, in most cases the diagnosis is made at about 4 months when the affected pups, which are notably smaller than unaffected littermates, suddenly begin to lick and bite their paws (1). This disease has been reported in German Short-Haired Pointers, English Pointers, English Springer Spaniels and French Spaniels as recessively inherited condition (1, 2).

AMS test:

Years of dedicated effort by the Canine Genetics Research team at University of Rennes (CNRS) in France led to discovery of the AMS mutation (3). ANTAGENE, a DNA research laboratory in France, has commercialized a DNA test that detects this mutation in the following breeds: English Cocker Spaniel, French Spaniel, English Springer Spaniel, English Pointer, German Shorthaired Pointer. OptiGen is pleased to assist North American owners of such breeds who wish to test their dogs for AMS. To make this test more convenient for these clients, OptiGen is serving as an agent for Antagene, by rendering blood or cheek swab samples into DNA and shipping the DNA to Antagene. Antagene owns the international license for testing Acral Mutilation Syndrome and will perform the DNA testing in their laboratory in France. OptiGen will obtain the results of the test from Antagene as soon as the tests are completed and send reports to the owners.

The Antagene DNA-based Acral Mutilation Syndrome (AMS) test distinguishes the mutant and the normal copy of the gene and allows separation of dogs into three groups: Normal/Clear (homozygous normal), Carrier (heterozygous) and Affected (homozygous mutated).

PLEASE NOTE: The Acral Mutilation Syndrome test is performed in the laboratories of Antagene in France. There is typically a 3-4 week delay after OptiGen receives a sample before AMS test results are available for reporting.

References:

1. Cummings JF et al (1983) Hereditary sensory neuropathy. Nociceptive loss and acral mutilation in pointer dogs: canine hereditary sensory neuropathy. Am J Pathol 112(1):136-138

2. Paradis M et al (2005) Acral mutilation and analgesia in 13 French spaniels. Vet Dermatol 16(2):87-93

3.  Plassais J, Lagoutte L, Correard S, Paradis M, Guagučre E, HeÂdan B, et al. (2016) A Point Mutation in a lincRNA Upstream of GDNF Is Associated to a Canine Insensitivity to Pain: A Spontaneous Model for Human Sensory Neuropathies. PLoS Genet 12(12): e1006482. doi:10.1371/journal.pgen.1006482

 


spacer
Graphic: footer bar left
OptiGen®, LLC · Cornell Business & Technology Park · 767 Warren Road, Suite 300 · Ithaca, New York 14850
Tel: 607 257 0301 · Fax: 607 257 0353 · email: genetest@optigen.com or optigen@clarityconnect.com
Graphic: footer bar right
spacer spacer
spacer
spacer
spacer